Platelet activating factor—a mediator of inflammation in the skin—medical implications
C. Archer
DOI: https://doi.org/10.1111/j.1365-2230.1993.tb01015.x
1993-11-01
Abstract:Platelet activating factor (PAF) was first described in 1972' as a soluble product of IgE-sensitized rabbit basophils capable of causing platelet aggregation. The structure of PAF was elucidated by three independent groups in 1979̂ ^ as l-O-alkyl-2-O-acetyl-sn-glyeerol-3phosphorylcholine (Fig. 1), an ether linked analogue of phosphatidyleholine. Alternative terms for PAF include PAF-aeether (Paf-acether), acetyl glyeeryl phosphorylcholine (AGEPC) or antihypertensive polar reno-medullary lipid (APRL). However, the original nomenelature of PAF is noŵ generally accepted. PAF is released from various inflammatory cell types, including platelets, neutrophils, monocytes, eosinophils and basophils, in response to both allergic and nonallergic stimuli.^ In addition to these eells, other possible cell sources of PAF in the skin include dermal microvascuiar endothelial cells or the resident skin cell population, including keratinocytes and fibroblasts.*'' Apart from its well-documented effects on platelets, PAF has a number of other actions appropriate to a mediator of inflamtnation, having been found to activate neutrophils," monocytes,'' eosinophils,'" basophils,"'and vascular endothe-. Hum.'-" Thus, PAF is chemotactic for neutrophils and will induce aggregation of neutrophils and monocytes, as well as producing superoxide anions in the latter cell type. There are two recognized biosynthetic pathways of PAF, the so-called 'remodelling' and de novo routes. The remodelling pathway seems to be limited to stimulated inflammatory cells (Fig. 2) and the de novo route is thought to be important for the production of basal physiological levels of PAF, necessary for the maintenance of cell membranes. The fact that these pathways utilize distinetly different enzyme systems may allow the targeting of therapy to inhibit PAF systems in infiammatory processes only. Although PAF produetion in the remodelling route involves phospholipase A2, with consequent release of araehidonate, PAF itself is not a product of the arachidonic acid cascade. The two-step synthetic